First Line Br In Chronic Lymphocytic Leukemia Patients: Interim Results Of Russian Norma Trial

Elena Stadnik,Vladimir Strugov, Tatyana Silina, Natalya Ilyina, Yulia Virts, Renat Badaev, Galina Kuchma,Elena Volodicheva,Tatyana Sycheva, Tatyana Kaporskaya,Kamil Kaplanov, Natalya Glonina, Lyubov Anchukova, Tatyana Byalik,Olga Samoilova,Elena Kirillova, Sergey Shklyaev, Yulia Mirolubova, Tatyana Nikulina,Andrey Rumyantsev, Andrey Proydakov, Irina Lysenko,Vladimir Melnichenko, Natalya Esefeva, Tatyana Ksenzova, Igor Davidkin, Olga Vasilyeva,Oksana Ochirova, Oleg Rukavitsyn, Natalya Bulieva, Vera Zherebtsova, Andrey Gubkin,Yulia Bogdanova, Irina Chebykina, Elena Shukaeva,Andrey Zaritskey

BLOOD（2014）

引用 2|浏览13

暂无评分

摘要

CLL is the disease of the elderly. Many CLL pts have high comorbidity burden, which makes them ineligible for intensive chemotherapy regimens like FCR. Recently, DCLLSG CLL10 trial proved comparable efficacy of BR and FCR regimens, but better tolerability of BR. It is thus conceivable that BR is a good treatment alternative for slow-go pts, particularly those with advanced chronic kidney disease.

查看译文

关键词

chronic lymphocytic leukemia patients,russian norma trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要